Breaking News Instant updates and real-time market news.

MU

Micron

$48.46

-1.38 (-2.77%)

, AKS

AK Steel

$4.37

-0.2 (-4.38%)

07:35
04/09/18
04/09
07:35
04/09/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Micron (MU), AK Steel (AKS), Lennar (LEN), AstraZeneca (AZN), AVEO Oncology (AVEO), McDermott (MDR), Hain Celestial (HAIN), Axalta Coating (AXTA), NewLink Genetics (NLNK), and Pacira (PCRX).

MU

Micron

$48.46

-1.38 (-2.77%)

AKS

AK Steel

$4.37

-0.2 (-4.38%)

LEN

Lennar

$61.58

-2.42 (-3.78%)

AZN

AstraZeneca

$35.42

0.07 (0.20%)

AVEO

Aveo Pharmaceuticals

$2.30

-0.06 (-2.54%)

MDR

McDermott

$5.61

-0.27 (-4.59%)

HAIN

Hain Celestial

$30.67

-0.04 (-0.13%)

AXTA

Axalta Coating

$32.47

0.74 (2.33%)

NLNK

NewLink Genetics

$4.20

-3.12 (-42.62%)

PCRX

Pacira

$33.30

3.8 (12.88%)

  • 14

    Apr

  • 16

    Apr

  • 23

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 08

    May

  • 21

    May

  • 30

    May

MU Micron
$48.46

-1.38 (-2.77%)

04/06/18
NOMU
04/06/18
NO CHANGE
Target $100
NOMU
Buy
Nomura keeps $100 target on Micron after positive management meetings
After spending two days meeting investors with Micron Technology's new CFO David Zinsner and Head of Investor Relations Shanye Hudson, Nomura Instinet analyst Romit Shah maintains a Buy rating on the shares with a $100 price target. The stock closed yesterday down $3.55 to $49.84 after UBS initiated the shares with a Sell rating. Shah says he left the meetings with "several positive takeaways." The analyst does not anticipate a "massive step-up" in capital expenditures next fiscal year. Further, management did not seem concerned that NAND selling price declines in the February period would persist, Shah tells investors in a research note. He adds that Micron continues to expect DRAM suppliers to be rational about capacity expansion in an effort to sustain high margins and cash flow.
04/05/18
04/05/18
NO CHANGE

UBS starts Semiconductors coverage, says sell Micron, Texas Instruments
UBS analyst Timothy Arcuri started coverage on the U.S. Semiconductors and Semi Equipment sector, expressing the view that consolidation and a slowdown in Moore's Law should actually lead to pricing power and inflationary effects that are still in the early innings. However, he also believes semis are still cyclical and sees some signs of caution moving into later 2018 and 2019. Arcuri, who is cautious on the memory cycle in the near-term, started Micron (MU) with a Sell rating and $35 price target, citing those cyclical memory concerns. He also has one other Sell rating among his 14 recommendations, on Texas Instruments (TXN), citing its fading leverage, a more level playing field for capital return and his cyclical concerns. Among the 14 stocks he initiated, Arcuri has 4 Buy ratings - Intel (INTC), given his above consensus call for datacenter group growth and what he sees as a mispricing of long-term growth potential; Marvell (MRVL) and Broadcom (AVGO), which he views as transformation stories; and KLA-Tencor (KLAC), on its migration to industrial tech and exposure to AI-related compute growth.
03/26/18
BERN
03/26/18
NO CHANGE
Target $60
BERN
Market Perform
Micron price target raised to $60 from $48 at Bernstein
Bernstein analyst Mark Newman raised his price target for Micron to $60 from $48, citing another record profit. However, the analyst reiterates a Market Perform rating on the shares on concerning capacity increases and NAND price weakness.
04/04/18
UBSW
04/04/18
INITIATION
Target $35
UBSW
Sell
Micron initiated with a Sell at UBS
UBS analyst Timothy Arcuri started Micron Technology with a Sell rating and $35 price target.
AKS AK Steel
$4.37

-0.2 (-4.38%)

03/02/18
FBCO
03/02/18
NO CHANGE
Target $48
FBCO
Outperform
Credit Suisse 'bullish' on U.S. steel sector following tariff announcement
Credit Suisse analyst Curt Woodworth said he is "bullish" on the U.S. steel sector following President Trump's announcement that he will implement 25% tariffs on steel and 10% tariffs on aluminum next week. In a research note to investors, Woodworth said his top picks in the sector are "volumetric winners" U.S. Steel (X) and Commercial Metals (CMC) and "price winners" Nucor (NUE) and Steel Dynamics (STLD), but he will await clarity on any exemption process before adjusting his price deck and earnings estimates.
03/09/18
COWN
03/09/18
NO CHANGE
COWN
Cowen sees upside for entire steel group with tariff decision
Cowen analyst Novid Rassouli said he sees upside for the entire steel group following the announced decision on tariffs for imported steel and aluminum. He said the entire steel group is trading at a discount to current spot steel prices. The analyst also believes Century Aluminum (CENX) will be the biggest beneficiary on the aluminum side, as he sees it as the best vehicle to capitalize. Publicly traded companies in the steel space include U.S. Steel (X), Steel Dynamics (STLD), AK Steel (AKS), Cleveland-Cliffs (CLF), Nucor (NUE) and ArcelorMittal (MT).
03/20/18
GSCO
03/20/18
INITIATION
Target $6
GSCO
Neutral
AK Steel initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Matthew Korn started AK Steel with a Neutral rating and $6 price target while rolling out coverage on the Americas Metals & Mining sector with an Attractive view.
03/29/18
DBAB
03/29/18
NO CHANGE
Target $50
DBAB
Buy
Correction in Steel stocks seems overdone, says Deutsche Bank
Deutsche Bank analyst Chris Terry believes the current fundamentals of Steel companies are not priced into the shares at current levels. He sees further earnings upgrades as companies report Q1 results and provide updated guidance. Terry thinks the correction in the shares appears overdone and keeps Buy ratings on Commercial Metals (CMC), US Steel (X), Reliance Steel (RS), AK Steel (AKS) and Ryerson (RYI). The analyst raised his price target for US Steel to $50 from $44.
LEN Lennar
$61.58

-2.42 (-3.78%)

02/13/18
JPMS
02/13/18
UPGRADE
Target $77
JPMS
Overweight
Lennar reinstated with an Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Rehaut upgraded Lennar (LEN) to Overweight with a $77 price target following a period of restriction. The analyst previously had a Neutral rating on the shares with a $57 price target. Lennar is attractively priced ahead of becoming a "significantly stronger company" as it integrates CalAtlantic (CAA) over the next 12-18 months, Rehaut tells investors in a research note. Lennar will likely have an "uncommonly strong market share" across most of the country following the deal, the analyst contends.
02/23/18
EVER
02/23/18
UPGRADE
EVER
Outperform
Lennar upgraded to Outperform from In Line at Evercore ISI
02/23/18
02/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FedEx (FDX) upgraded to Outperform from Market Perform at Bernstein with analyst David Vernon saying he expects revenue and earnings growth to be driven by a strengthening global economy and rising interest rates, the tightening domestic transportation market and demand for B2C delivery. 2. BT Group (BT) upgraded to Buy from Hold at Berenberg. 3. Financial Engines (FNGN) upgraded to Outperform from Market Perform at William Blair with analyst Robert Napoli citing the company's "strong" quarter. 4. Lennar (LEN) upgraded to Outperform from In Line at Evercore ISI. 5. Devon Energy (DVN) upgraded to Buy from Hold at KLR Group with analyst John Gerdes noting that the stock is down over 30% and has significantly underperformed the sector since late January, when he had previously downgraded it. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/18
MZHO
04/05/18
NO CHANGE
Target $80
MZHO
Buy
Lennar valuation favorable with more earnings upside ahead, says Mizuho
Mizuho analyst Haendel St. Juste says Lennar's posted "solid" Q1 results on better than expected joint venture income and margins. The analyst sees "even more" earnings upside ahead after Lennar outlined additional fiscal 2018 synergy potential and remained optimistic on the housing backdrop. St. Juste views the current valuation as favorable and maintains a Buy rating on the shares with an $80 price target.
AZN AstraZeneca
$35.42

0.07 (0.20%)

04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.
03/14/18
HCWC
03/14/18
NO CHANGE
Target $6
HCWC
Buy
Advaxis drug unlikely culprit of patient death, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Advaxis (ADXS) to $6 from $23 after the FDA placed a clinical hold on the Phase 1/2 study investigating the combination of the company's axalimogene filolisbac and AstraZeneca's (AZN) durvalumab for the treatment of HPV-associated cervical and head and neck cancers. Based on its previous safety profile, axalimogene is unlikely to be the cause of death for this patient, Ramakanth tells investors in a research note. The analyst, however, notes that it would likely take several months before the FDA is able to reach a decision and lift the clinical hold. He anticipates a one-to-two quarter delay to the axal plus durva combination therapy program but keeps a Buy rating on Advaxis shares.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/18
JEFF
03/19/18
UPGRADE
JEFF
Buy
AstraZeneca upgraded to Buy from Hold at Jefferies
Jefferies analyst Ian Hilliker upgraded AstraZeneca to Buy and raised his price target for the shares to 5,600p from 5,075p. The company is at a "turning point," Hilliker tells investors in a research note. He believes accelerating new product launches and improving margins should deliver over 20% core earnings growth in the mid-term. Recovering growth, driven by the underlying business warrants a "modest mid-term premium valuation," the analyst contends.
AVEO Aveo Pharmaceuticals
$2.30

-0.06 (-2.54%)

11/13/17
RILY
11/13/17
INITIATION
Target $5
RILY
Buy
Aveo Oncology initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Aveo Oncology with a Buy rating and $5 price target. The analyst sees the company's lead asset, vascular endothelial growth factor receptor tyrosine kinase inhibitor Fotivda, being successful in the pivotal Tivo-3 trial reading out in Q1 of 2018. He views the drug as undervalued.
11/13/17
11/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Party City (PRTY) assumed with an Overweight at JPMorgan. 2. MongoDB (MDB) was initiated with a Buy at Stifel and Canaccord, an Overweight at Barclays, an Equal Weight at Morgan Stanley, a Market Perform at JMP Securities, and a Neutral at Goldman Sachs. 3. Arista Networks (ANET) initiated with a Neutral at Piper Jaffray. 4. NetScout (NTCT) initiated with an Overweight at Piper Jaffray. 5. Aveo Oncology (AVEO) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/18
PIPR
03/29/18
NO CHANGE
Target $5
PIPR
Overweight
Aveo Oncology should be bought ahead of Phase III data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Aveo Oncology to report Phase III Tivo-3 data in third-line renal cell carcinoma in Q2. The analyst is confident tivozanib will achieve a statistically significant survival benefit over Nexavar and recommeds buying the stock ahead of the readout. Positive data will enable Aveo to respond to the 2013 tivozanib complete response letter with potential FDA approval in 2019, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $5 price target.
10/06/17
GHSC
10/06/17
INITIATION
Target $7
GHSC
Buy
AVEO Oncology initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated AVEO Oncology with a Buy and $7 price target.
MDR McDermott
$5.61

-0.27 (-4.59%)

01/24/18
KEYB
01/24/18
UPGRADE
Target $14
KEYB
Overweight
McDermott upgraded to Overweight with $14 target at KeyBanc
KeyBanc analyst Tahira Afzal upgraded McDermott (MDR) to Overweight from Sector Weight with a $14 price target. The analyst expects a "step-up in execution" at CB&I (CBI) following the merger and has confidence in a sustained improvement in the energy macro environment. He believes the deal will create value.
01/23/18
KEYB
01/23/18
UPGRADE
KEYB
Overweight
McDermott upgraded to Overweight from Sector Weight at KeyBanc
12/20/17
MSCO
12/20/17
NO CHANGE
MSCO
Underweight
McDermott may have hard time recognizing CB&I synergies, says Morgan Stanley
Morgan Stanley analyst Ole Slorer said he sees room for concern over McDermott's (MDR) deal to combine in an all-stock transaction with CB&I (CBI). McDermott's "pristine" balance sheet and improved execution could be hurt by CBI's recent execution challenges and "higher than optimal" debt, while synergies from the merger may be difficult to realize, contends Slorer, who keeps an Underweight rating on McDermott shares.
12/19/17
DADA
12/19/17
DOWNGRADE
Target $19
DADA
Neutral
CB&I downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Brent Thielman downgraded CB&I (CBI) to Neutral from Buy and lowered his price target to $19 from $25 after the company entered into a merger agreement with McDermott International (MDR). Thielman says that CB&I's execution challenges reduce the likelihood of a competitive bid, adding that he expects the deal to pass regulatory requirements.
HAIN Hain Celestial
$30.67

-0.04 (-0.13%)

11/21/17
WELS
11/21/17
NO CHANGE
WELS
Nestle acquisition of Hain makes sense, says Wells Fargo
Wells Fargo analyst John Baumgartner believes a Nestle (NSRGY) acquisition of Hain Celestial (HAIN) would make sense. Bloomberg last night reported that Nestle is among the companies exploring a purchase of Hain. Nestle would likely be a good fit for Hain's baby food, skin care and tea businesses, Baumgartner told investors earlier in a research note. The analyst sees "tax leakage" as a headwind for any deal and keeps a Market Perform rating on Hain with a $38 price target.
12/19/17
MAXM
12/19/17
NO CHANGE
MAXM
Buy
Hain Celestial could be attractive target for CPG manufacturers, says Maxim
Maxim notes that it has observed consolidation in the consumer-packaged goods industry over the past three months, particularly in the area of healthy snacking. Seeing Hain Celestial as a leading producer of better-for-you snacks, the firm believes the company could be an attractive acquisition target for consumer-packaged goods manufacturers seeking to take advantage of the health and wellness trend within snack foods. Based on Maxim's analysis of comparable transactions, it thinks the starting point for a potential acquisition of Hain would be $55-$60 per share.
02/08/18
BMOC
02/08/18
NO CHANGE
Target $39
BMOC
Market Perform
Hain Celestial price target lowered to $39 from $44 at BMO Capital
BMO Capital analyst Amit Sharma lowered his price target on Hain Celestial to $39 after a Q2 earnings miss. Sharma says the company's FY18 EBITDA guidance, which assumes a "huge margin ramp" in the second half of the year, is unrealistic in light of "rising commodity and freight inflation, unfavorable product mix, and potentially higher investments". The analyst keeps his Market Perform rating on Hain Celestial.
12/22/17
LOOP
12/22/17
NO CHANGE
Target $38
LOOP
Hold
Hain unlikely to receive premium in a takeover, says Loop Capital
Following the acquisitions of Amplify Snack Brands (BETR) and Snyder's-Lance (LNCE), Loop Capital analyst Andrew Wolf revisited his outlook for Hain Celestial Group (HAIN) as an acquisition candidate. The analyst's sum-of-the-parts valuation range for the company remains at $42 to $56 per share, representing a premium range of 1% to 35% to the current share price. Hain, however, is not likely to receive much of a premium valuation in a takeout because its core domestic business is barely growing, in contrast to the companies that have been acquired, Wolf tells investors in a research note. He keeps a Hold rating on the stock with a $38 price target.
AXTA Axalta Coating
$32.47

0.74 (2.33%)

03/27/18
BMOC
03/27/18
INITIATION
Target $33
BMOC
Market Perform
Axalta Coating initiated with a Market Perform at BMO Capital
BMO Capital analyst John McNulty started Axalta Coating with a Market Perform rating and $33 price target.
03/27/18
SBSH
03/27/18
NO CHANGE
SBSH
Citi says AkzoNobel free to think more strategically about M&A after divestiture
After AkzoNobel (AKZOY) announced the sale of its Specialty Chemicals business to Carlyle Group (CG) and GIC, Citi analyst P.J. Juvekar said the divestiture frees up the company to think more strategically about M&A. Akzo could go after Axalta (AXTA) again, but unless Akzo is prepared to pay a significant premium a deal is unlikely, said Juvekar. He thinks a price in the mid to high $30 range would be needed to get Axalta to the negotiating table. Akzo has thus far resisted a sale to PPG (PPG), but Juvekar thinks PPG would be interested if a deal were to be a friendly one.
01/16/18
BOFA
01/16/18
INITIATION
Target $28
BOFA
Underperform
Axalta Coating resumed with an Underperform at BofA/Merrill
BofA/Merrill analyst Steve Byrne resumed coverage on Axalta Coating with an Underperform and $28 price target following the company's disclosure it is no longer in M&A discussions. The analyst said Axalta shares are trading towards the high-end of its historical range despite negative EBITDA growth in 2017 and only modest expectations for a growth rebound in 2018. Additionally, the firm's automotive team expects a the cyclical downturn in US auto sales to continue and views increasing penetration of collision avoidance technology and autonomous vehicles as a longer-term structural risk to Axalta's refinish business.
01/16/18
01/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Axalta Coating (AXTA) resumed with an Underperform at BofA/Merrill. 2. UBS (UBS) and Credit Suisse (CS) were initiated with an Underweight at Barclays. 3. Nutrien (NTR) initiated with a Neutral at Goldman Sachs. 4. Cambrex (CBM) initiated with an Outperform at William Blair. 5. Dicerna (DRNA) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NLNK NewLink Genetics
$4.20

-3.12 (-42.62%)

04/09/18
RHCO
04/09/18
DOWNGRADE
Target $5
RHCO
Hold
NewLink Genetics downgraded to Hold at SunTrust on Incyte trial failure
As reported late last week, SunTrust analyst Peter Lawson downgraded NewLink Genetics (NLNK) to Hold from Buy and lowered his price target to $5 from $19. Lawson cites the announcement of negative results from the Phase 3 ECHO-301 of epacadostat + Keytruda in melanoma by Incyte (INCY), saying the data also implies a "significant negative read through for NewLink's IDO agent, indoximod". Lawson adds that the results have led him to remove melanoma from his NewLink model and also reduce the probability of success in pancreatic cancer, lowering the probability of adjusted peak sales from $415M to just $11M.
04/09/18
CANT
04/09/18
DOWNGRADE
CANT
Neutral
NewLink Genetics downgraded to Neutral from Overweight at Cantor Fitzgerald
04/09/18
CANT
04/09/18
DOWNGRADE
Target $7
CANT
Neutral
Cantor downgrades NewLink with $7 target on added indoximod uncertainty
Cantor Fitzgerald analyst Mara Goldstein downgraded NewLink Genetics (NLNK) to Neutral from Overweight and cut her price target for the shares to $7 from $26. The analyst cites NewLink's decision to revisit the indoximod clinical program as the reason for the downgrade. Goldstein previously highlighted the differentiating factors between indoximod and Incyte's (INCY) epacadostat, but she now has reduced confidence given a "lack of decisive commentary" from NewLink management.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
PCRX Pacira
$33.30

3.8 (12.88%)

04/09/18
HCWC
04/09/18
NO CHANGE
Target $48
HCWC
Buy
Pacira price target raised to $48 from $45 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat raised his price target for Pacira Pharmaceuticals to $48 after the FDA approved an additional "narrow" nerve block indication for Exparel. The FDA added a specific interscalene brachial plexus block indication for regional anesthesia, effectively an indication for shoulder replacement or rotator cuff repair, Livnat tells investors in a research note. While a broad general nerve block indication would have been best case, and Pacira has to be careful not to promote off-label, this is still an "important positive," the analyst contends. He reiterates a Buy rating on Pacira shares.
04/09/18
JPMS
04/09/18
NO CHANGE
JPMS
Neutral
Pacira nerve block approval a 'clear positive,' at JPMorgan
In a research note partially titled "Something's Better Than Nothing," JPMorgan analyst Chris Schott says Friday night's FDA approval for nerve block is a "clear positive" for Pacira Pharmaceuticals. He notes that the Street broadly expected a Complete Response Letter for Exparel in this indication. While the approval does not include a broad nerve block label, it does allow Pacira to target 1M shoulder blocks performed annually, Schott tells investors. However, the Exparel label update also included several failed nerve block studies that should limit off label use of the drug, the analyst adds. He keeps a Neutral rating on Pacira.
04/09/18
PIPR
04/09/18
NO CHANGE
Target $44
PIPR
Overweight
Piper reiterates Overweight on Pacira after 'watershed' nerve block approval
FDA approval of Pacira Pharmaceuticals' (PCRX) Exparel as a brachial plexus block "is something of a watershed" in that the agency has never before approved any local or regional anesthetic for a single, specific setting, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the approval suggests an increasingly aggressive FDA approach towards the opioid crisis. Amsellem points out, however, that feedback from his surgeon survey suggests a "strong degree of enthusiasm" for Heron Therapeutics' (HTRX) HTX-011. However, the feedback also indicates that non-opioid, post-operative pain space is not a zero-sum game, the analyst writes. He believes Exparel can grow "even amid greater competition." Amsellem reiterates an Overweight rating on Pacira with a $44 price target.
04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.

TODAY'S FREE FLY STORIES

EWW

iShares MSCI Mexico

$49.18

-0.055 (-0.11%)

06:45
08/17/18
08/17
06:45
08/17/18
06:45
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.59

-0.01 (-0.04%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$21.16

(0.00%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

, EQGP

EQT GP

$22.25

0.2 (0.91%)

06:43
08/17/18
08/17
06:43
08/17/18
06:43
Recommendations
EQT Midstream Partners, EQT GP analyst commentary  »

EQT Midstream price…

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

EQGP

EQT GP

$22.25

0.2 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$49.85

0.61 (1.24%)

06:41
08/17/18
08/17
06:41
08/17/18
06:41
Recommendations
EQT Corporation analyst commentary  »

EQT Corporation price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$15.64

0.13 (0.84%)

06:37
08/17/18
08/17
06:37
08/17/18
06:37
Initiation
Cott Corp. initiated  »

Cott Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.03

-0.0172 (-36.44%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Periodicals
MoviePass puts additional restrictions on subscribers, NY Post says »

MoviePass chief Mitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFET

Safe-T

$0.00

(0.00%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Syndicate
Safe-T raises $7.335M in a registered direct offering »

Safe-T announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.83

0.44 (1.36%)

, FB

Facebook

$174.76

-4.78 (-2.66%)

06:33
08/17/18
08/17
06:33
08/17/18
06:33
Periodicals
Twitter CEO criticizes Facebook, YouTube for Alex Jones' removal, BI reports »

Twitter (TWTR) CEO Jack…

TWTR

Twitter

$32.83

0.44 (1.36%)

FB

Facebook

$174.76

-4.78 (-2.66%)

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 06

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

AZRE

Azure Power

$15.95

-0.405 (-2.48%)

06:30
08/17/18
08/17
06:30
08/17/18
06:30
Initiation
Azure Power initiated  »

Azure Power initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

$0.00

(0.00%)

, AAPL

Apple

$213.49

3.21 (1.53%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Periodicals
Foxconn to launch semiconductor plant in China's Pearl River Delta, WSJ says »

Foxconn Technology, …

HNHPF

Hon Hai Precision

$0.00

(0.00%)

AAPL

Apple

$213.49

3.21 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMC

Yum China

$35.33

0.29 (0.83%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Downgrade
Yum China rating change  »

Yum China downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LGND

Ligand

$239.84

-7.88 (-3.18%)

06:25
08/17/18
08/17
06:25
08/17/18
06:25
Initiation
Ligand initiated  »

Ligand initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

, GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

06:24
08/17/18
08/17
06:24
08/17/18
06:24
Periodicals
Google CEO responds to criticism over plan for search engine in China, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

BXG

Bluegreen Vacations

$20.39

-0.65 (-3.09%)

06:22
08/17/18
08/17
06:22
08/17/18
06:22
Downgrade
Bluegreen Vacations rating change  »

Bluegreen Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:21
08/17/18
08/17
06:21
08/17/18
06:21
Earnings
Deere reports Q3 EPS 2.78, consensus $2.75 »

Reports Q3 worldwide net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

WMT

Walmart

$98.63

8.39 (9.30%)

, COST

Costco

$223.20

1.55 (0.70%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Walmart, Costco, Target analyst commentary  »

Walmart price target…

WMT

Walmart

$98.63

8.39 (9.30%)

COST

Costco

$223.20

1.55 (0.70%)

TGT

Target

$82.07

1.38 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Oct

KORS

Michael Kors

$71.94

0.63 (0.88%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Michael Kors analyst commentary  »

Michael Kors price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

ENB

Enbridge

$34.89

-0.19 (-0.54%)

06:18
08/17/18
08/17
06:18
08/17/18
06:18
Upgrade
Enbridge rating change  »

Enbridge upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$53.58

1.24 (2.37%)

06:17
08/17/18
08/17
06:17
08/17/18
06:17
Recommendations
Dave & Buster's analyst commentary  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:16
08/17/18
08/17
06:16
08/17/18
06:16
Hot Stocks
Deere CEO says 'continue face cost pressures for raw materials and freight' »

"Deere's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

FB

Facebook

$174.76

-4.78 (-2.66%)

06:15
08/17/18
08/17
06:15
08/17/18
06:15
Periodicals
Facebook begins to crack down on opioid dealers, TechCrunch reports »

Facebook's internal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

TM

Toyota

$122.76

0.9 (0.74%)

06:14
08/17/18
08/17
06:14
08/17/18
06:14
Periodicals
Toyota to boost production capacity in China by 20%, Reuters says »

Toyota will add more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:13
08/17/18
08/17
06:13
08/17/18
06:13
Earnings
Deere sees FY18 equipment revenue up about 30%, consensus $33.78B »

Company equipment sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

SUI

Sun Communities

06:12
08/17/18
08/17
06:12
08/17/18
06:12
Downgrade
Sun Communities rating change  »

Sun Communities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.